Fig. 4
Response to therapeutic drugs in human PDAC patient-derived organoids and PDAC cell lines. a and b Human PDAC PDOs and c and d PDAC cell lines were treated with gemcitabine, nab-paclitaxel, irinotecan, and Olaparib for 7 days. Cell viability was assessed using adenosine triphosphate monitoring (in triplicate). Dose–response curves were fitted, and the half-maximal inhibitory concentration (IC50) values (nM) were calculated. ORG2383 and PK59 are Galc carriers